CSU Receives $2 Million Grant to Help Prevent Future Pandemics

Building on its response to the COVID-19 pandemic, Colorado State University has received a $2 million commitment from The Anschutz Foundation to further the development of new solutions for building...

Learn More

Evergreen Research Appoints New President, Natasha Bond

Evergreen Research, Inc. (Evergreen), a leading provider of contract development, manufacturing, and regulatory/quality assurance services, is pleased to announce the appointment of Natasha (Tasha) Bo...

Learn More

Nasal-Spray Combined Vaccine for Covid and Flu Shows Protection

Vivaldi Biosciences, a clinical-stage biotechnology company developing genetically engineered intranasal vaccines for viral respiratorydiseases, today announced positive preclinical data supporting fu...

Learn More

Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, t...

Learn More

LightDeck Diagnostics Appoints Nick Traggis as CEO to Scale Company Operations Through Next Phase of Growth

 LightDeck Diagnostics today announced that Nick Traggis has transitioned from executive vice president of Corporate Development to Chief Executive Officer (CEO). Chris Myatt, who precedes M...

Learn More

TANOVEA® (rabacfosadine for injection) Receives Full FDA Approval as First Treatment for Lymphoma in Dogs; Elanco Acquires Product from VetDC, Inc

Elanco Animal Health Incorporated (NYSE: ELAN) announced that the  FDA has granted full approval of Tanovea for the treatment of lymphoma in dogs, making this the first conditionally approved new...

Learn More

FDA Grants First Full Approval for Treatment of Lymphoma in Dogs

Today, the U.S. Food and Drug Administration fully approved Tanovea (rabacfosadine injection) to treat lymphoma in dogs. Lymphoma, also called lymphosarcoma, is a type of cancer that can affect many s...

Learn More

Long-time CBSA Member Aerotek to Change Name

Aerotek, a leading talent solutions provider, today revealed that its three highly specialized business units—Industrial, Professional, and Engineering and Sciences—have separated into independen...

Learn More

ARCA Biopharma Provides Update On Aspen-COVID-19 Phase 2B Clinical Trial Evaluating RNAPC2 as a Potential Treatment for COVID-19

CBSA Member ARCA Biopharama is receiving approvals from regulators in Argentina and Brazil to test your possible COVID-19 treatment. Find out more in the press release.

Learn More

VitriVax Announces Series A Financing to Further Demonstrate Feasibility of its Thermostable, Single-Dose Vaccine Technology, Aiming to Make Life-Saving Biologics Widely Accessible to Underserved Populations Globally

VitriVax, developer of a novel stabilization and delivery platform for vaccines and therapeutics, today announced it has closed its first institutional financing round with Adjuvant Capital. Series A...

Learn More